A Study of Peluntamig (PT217) in Patients with Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.
Small Cell Lung Cancer (SCLC)|Large Cell Neuroendocrine Cancer (LCNEC)|Neuroendocrine Prostate Cancer (NEPC)|Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)|Neuroendocrine Carcinomas (NEC)|Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
DRUG: Peluntamig (PT217)|DRUG: Carboplatin + Etoposide|DRUG: Paclitaxel.|DRUG: Atezolizumab
To determine the dose-limiting toxicity (DLT) of Peluntamig (PT217)., Through study completion.|To determine the maximum tolerated dose (MTD) of Peluntamig (PT217) if reached., Through study completion.|To determine recommended dose for expansion (RDE) of Peluntamig (PT217)., Through study completion.|To evaluate the safety and tolerability of Peluntamig (PT217)., Through study completion.
To evaluate the pharmacokinetics of Peluntamig (PT217)., Through study completion.|To evaluate the immunogenicity (ADA) of Peluntamig (PT217)., Through study completion.|To evaluate the preliminary efficacy of Peluntamig (PT217)., Through study completion.
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.